drugset / Trial / NCT07676266
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
Phase 1
Not yet recruiting
18 enrolled
The Affiliated Hospital of Qingdao University
Shanghai AbelZeta Ltd. · collab
NaSequentialOpen-labelTreatment
Summary
This is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard therapy
Timeline
- Start
- 2026-07
- Primary completion
- 2027-11
- Completion
- 2028-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | C-CAR168 | Cell therapy | — | Intravenous |